Table 4 Logistic regression for prediction of carrier status based on family history in 191 families with at least one affected individual tested.
| Family characteristics* | OR | p Value (95% CI) |
|---|---|---|
| BRCA1+ v no mutation detected | ||
| 0–1 cases Br Ca <50 years | 1 (Ref) | |
| 2–3 cases Br Ca <50years | 4.7 | 0.12 (0.7 to 32.8) |
| ⩾4 cases Br Ca <50 years | 46.3 | 0.001 (4.8 to 443) |
| 0–1 cases Br Ca ⩾50 years | 1 (Ref) | |
| 2–3 cases Br Ca ⩾50 years | 0.2 | 0.022 (0.04 to 0.8) |
| ⩾4 cases Br Ca ⩾50 years | 0.1 | 0.10 (0.01 to 1.5) |
| No Ov Ca | 1 (Ref) | |
| 1 case Ov Ca | 10.6 | 0.005 (2.0 to 54.7) |
| ⩾2 cases Ov Ca | 284 | <0.001 (33 to 2466) |
| ⩾1 male Br Ca v none | 24.8 | 0.076 (0.7 to 868) |
| ⩾1 bilateral Br Ca v none | 7.5 | 0.014 (1.5 to 37) |
| BRCA2+ v no mutation detected | ||
| 0–1 cases Br Ca <50 years | 1 (Ref) | |
| 2–3 cases Br Ca <50 years | 1.7 | 0.39 (0.5 to 5.7) |
| ⩾4 cases Br Ca <50 years | 5.9 | 0.010 (1.5 to 23) |
| 0–1 cases Br Ca ⩾50 years | 1 (Ref) | |
| 2–3 cases Br Ca ⩾50 years | 0.5 | 0.22 (0.1 to 41.6) |
| ⩾4 cases Br Ca ⩾50 years | 0.9 | 0.94 (0.2 to 53.6) |
| No Ov Ca | 1 (Ref) | |
| 1 case Ov Ca | 1.6 | 0.48 (0.4 to 4.7) |
| ⩾2 cases Ov Ca | 17.0 | <0.001 (3.7 to 78) |
| ⩾1 male Br Ca v none | 13.7 | 0.004 (2.3 to 80) |
| ⩾1 bilateral Br Ca v none | 3.7 | 0.019 (1.2 to 11) |
| BRCA1/BRCA2+ v no mutation detected | ||
| 0–1 cases Br Ca <50 years | 1 (Ref) | |
| 2–3 cases Br Ca <50 years | 2.4 | 0.12 (0.8 to 7.2) |
| ⩾4 cases Br Ca <50 years | 10.4 | <0.001 (3.1 to 36) |
| 0–1 cases Br Ca ⩾50 years | 1 (Ref) | |
| 2–3 cases Br Ca ⩾50 years | 0.4 | 0.047 (0.13 to 0.99) |
| ⩾4 cases Br Ca ⩾50 years | 0.6 | 0.37 (0.16 to 2.10) |
| No Ov Ca | 1 (Ref) | |
| 1 case Ov Ca | 2.8 | 0.059 (0.9 to 67.9) |
| ⩾2 cases Ov Ca | 51 | <0.001 (13.5 to 195) |
| ⩾1 male Br Ca v none | 14.8 | 0.004 (2.4 to 91) |
| ⩾1 bilateral Br Ca v none | 5.2 | 0.001 (1.9 to 14.1) |
Br, breast; Ca, cancer; Ov, ovarian.
*Female breast and ovarian cancer cases were at most third‐degree relatives of the proband, whereas the presence of male patients with breast cancer was considered at any degree from the proband; 10 cases of ductal carcinoma in situ included.